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Background: The role of vascular endothelial growth factor (VEGF) in patients in the stable phase after myocardial
infarction (MI) has not yet been explored. Therefore, we compared the values of VEGF in post-MI patients with those
obtained in healthy controls. Furthermore, we investigated whether the values of VEGF correlate to either inflammation
markers or the atherosclerotic burden.
Methods: 41 male patients (on average 44 years old) in the stable phase after MI (on average 20.5 months after MI)
were recruited, while 25 healthy age-matched males served as controls. Plasma levels of VEGF and several markers of
inflammation were measured by standard procedures. The atherosclerotic burden was determined by the angiographic
severity of coronary atherosclerosis, endothelial dysfunction (measured by ultrasound measurement of the flow mediated
dilation of the brachial artery), the intima-media thickness of the common carotid artery and the ankle-brachial pressure
index.
Results: VEGF values were significantly elevated in post-MI patients compared to the controls (53.8 ± 42.7 pg/ml vs.
36.3 ± 8.9 pg/ml, p = 0.014). The elevated VEGF values significantly correlated to the (increased) values of the inflammatory
molecules interleukin 6 and 8 (r = 0.37, p = 0.017; and r = 0.45, p = 0.003; respectively). In contrast, no correlation was found
between VEGF and the parameters of the atherosclerotic burden, although FMD and IMT were significantly impaired in
patients.
Conclusions: We found that plasma levels of VEGF are increased in the stable phase after MI and correlate with
inflammation cytokines, but not with the atherosclerotic burden. Thus, this suggests that increased levels of VEGF are a
part of ongoing inflammatory activity. Since VEGF in these patients stimulates neovascularization of inflamed plaques and
induces their destabilization, the VEGF level can have an important negative prognostic value. Clearly, further studies are
needed to clarify the role of VEGF as a prognostic marker.
Keywords: Vascular endothelial growth factor, Inflammation markers, Interleukin 6, Interleukin 8, Endothelial dysfunction,
Myocardial infarction, Young adult patientsBackground
VEGF induces angiogenesis in several physiological
conditions (for example embryogenesis), as well as in
pathological states (for example tumour growth).
VEGF induces angiogenesis through the formation of
new vessels as a compensatory process in myocardial
ischemia, but on the other hand, it can also be a mechanism* Correspondence: erzen_b@yahoo.com
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unless otherwise stated.producing destabilization of atherosclerotic plaques in
coronary arteries [1-5]. Understanding of these evidently
different roles of VEGF is still insufficient. Besides VEGF,
several other angiogenic markers are known such as
angiogenin, hepatocyte growth factor and basic fibroblast
growth factor, though undoubtedly VEGF is the key angio-
genic molecule. However, as mentioned above, its ability to
assume either a pro-atherosclerotic or an anti-atherosclerotic
role is somewhat confusing and still insufficiently explained.
There is only scare and conflicting data about the role
of VEGF in coronary artery disease. Studies have showntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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MI, as a response to myocardial ischemia. In acute MI
patients who successfully underwent primary percutaneous
intervention (PCI), VEGF levels reach their peak at day 7
[6-9], and return to normal after about 6 months [10].
There are conflicting data about the prognostic meaning of
VEGF levels in the acute phase after MI. In a recently
published Japanese prospective multicentre study it
was shown that low levels of VEGF in the acute
phase of MI are associated with a worse 6 months
prognosis. In this study the incidence of recurrent
acute coronary syndrome and stroke were significantly
higher in the low VEGF group [6]. On the other hand, and
in complete contrast, a European study showed that high
VEGF levels in the acute phase of MI are related to an
adverse outcome during a 6 months follow-up [11].
Discussing these conflicting results one could only
conclude that VEGF may have an important prognostic
value, but one which surprisingly may be positive or
negative. From the clinical point of view it is even
more important to investigate the role of VEGF in the
stable phase of the disease.
Therefore the aim of the present study was to investigate
whether VEGF is increased in the stable phase of coronary
artery disease and to explore its role in this period. For this
purpose we compared serum levels of VEGF in young
post-MI patients and healthy age-matched controls.
Furthermore, we were interested whether VEGF is related
to the severity of inflammation (indicated by increased
levels of serum inflammatory molecules) or to the degree
of atherosclerotic burden. If associated with inflammation
it could be deduced that VEGF probably has a negative
angiogenic role in the inflammatory process inducing
destabilization of plaques, whereas if associated with the
atherosclerotic burden this suggests that it has a positive
angiogenic role inducing angiogenesis in ischemic areas.
Methods
Study population
The study group consisted of 41 patients with coronary
heart disease. In all patients MI was defined by a positive
troponin level, ECG changes and obstructive coronary
lesions confirmed by angiography. Inclusion criteria were
male gender, age at the time of myocardial infarction less
than 50 years, more than 6 months and less than 3 years
from the time of MI to the time of the trial performance
(an average of 20.5 months), and coronary artery disease in
the stable period (absence of unstable AP). Exclusion cri-
teria were malignancy, heart failure, an acute inflammation
state 14 days before the study, a history of diabetes mellitus,
anticoagulant therapy, and the use of any other drugs
except ACE inhibitors, beta blockers, antiplatelet drugs and
statins. We divided the patients into three groups (one, two
or three vessel disease) according to the number of diseasedvessels seen on the coronarography at the time of MI.
Significant stenosis was determined as stenosis above 50%.
The control group consisted of 25 healthy male volun-
teers, who did not differ from the patients regarding age
and had no manifested atherosclerotic disease.
All subjects were informed about the study protocol and
gave their informed consent. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration of
Helsinki, and was approved by the State Ethics Committee
of Slovenia.
Clinical examination and laboratory procedures
One visit by the subjects was necessary at which their
medical history was recorded, and a clinical examination,
biochemical tests and ultrasound measurements were
performed. All ultrasound measurements were performed
in the morning. Patients were on their regular therapy and
had taken their usual dose of morning medicine. Any
smokers abstained from smoking on that day.
A detailed family and personal history was recorded, and
a clinical examination performed according to a question-
naire. Systolic and diastolic blood pressures were measured
with a mercury sphygmomanometer after a minimum of
10-min rest in the sitting position. The average of three
measurements was taken. Anthropometric parameters were
determined, and BMI was calculated as weight in kilograms
divided by the square of the height in meters, and WHR
was calculated as waist size divided by hip size.
Blood for laboratory analysis was collected in the
morning after a 12-hour overnight fast. Samples were
drawn from the antecubital vein. Blood for the analysis
of glucose and lipids was collected without additives,
centrifuged and samples of serum were analysed.
Concentrations of glucose, total cholesterol, high density
lipoprotein (HDL) cholesterol and triglycerides were
determined by standard colorimetric assays from the
fresh samples of serum (Ektachem 250 Analyzer, Eastman
Kodak Company, Rochester, USA). Low density lipoprotein
(LDL) cholesterol was calculated using Friedewald's
formula. High sensitivity CRP (hsCRP) was measured
with a fully automated, latex-enhanced nephelometric
immunoassay (N High Sensitivity CRP, Dade Behring
Marburg, Germany).
Concentrations of VEGF, angiogenin and interleukin-8
(IL-8were measured by Cytometric Bead Array (BD
Biosciences Pharmingen, San Diego, CA, USA) con-
taining microparticles dyed to different fluorescence
intensities. The anaphylatoxin-captured beads were
incubated with standards (purified from human plasma)
or test samples followed by a wash and incubation
with phycoerythrin-conjugated detection antibodies to
form sandwich complexes. Flow cytometric analysis
was performed using a FACSCalibur flow cytometer
(Becton Dickinson Immunocytometry Systems, BDIS,
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and analysed using the Beckton Dickinson Cytometric
bead array (CBA) software.
Serum tumour necrosis factor- α (TNF-α) (Quantikine®
HS Human TNF- α Immunoassay, R&D Systems, USA),
interleukin-6 (IL-6) (Quantikine® Human IL-6 Immunoassay,
R&D Systems, USA) and the serum cell adhesion
molecules ICAM-1, VCAM-1, selectin-P, selectin-E
(Parameter® ICAM-1, Parameter® VCAM-1, Parameter®
selectin-P, Parameter® selectin-E, R&D Systems UK) were
determined by enzyme-linked immunosorbent assays.
Vascular studies
a.) Measurement of endothelial dysfunction (ED);
Flow mediated (FMD) (endothelium-dependent) and
glyceryl trinitrate (GTN)-induced dilation (endothelium-
independent) of the right brachial artery were studied
using a high-resolution B mode Diasonics VST ultrasound
system with a 10 MHz linear array transducer. The
subjects rested in the supine position for ten minutes
before hemodynamic measurements were performed.
The right brachial artery was scanned in the longitudinal
section 2 to 15 cm above the elbow to find the clearest
images of the anterior and posterior wall layers. The mean
arterial diameter was measured at the end of the diastole,
which was determined by simultaneous monitoring of the
electrocardiogram (concurrent with onset of the QRS
complex). At least three cardiac cycles were analysed for
each scan and the measurements averaged. The flow
velocity was measured at a fixed incident angle of 68° to the
vessel with the range gate of 1.3 mm located in the centre
of the artery. The baseline blood flow was estimated by
multiplying the velocity time integral of the Doppler flow
signal (corrected for incident angle) by the vessel cross-
sectional area. Hyperemic flow increase was induced by
inflation of a blood pressure tourniquet placed around the
forearm to a pressure of 300 mmHg for 4.5 minutes.
Hyperemic flow was recorded for the first 15 seconds and
diameter measurements were taken 45–60 seconds after
cuff deflation. The endothelium-dependent dilation was
expressed as the percentage change of the diameter after
reactive hyperaemia, relative to the baseline scan. Ten
minutes were allowed for vessel recovery, after which a
further resting scan was taken. A sublingual tablet of
0.5 mg of GTN was then administered, and 4.5 minutes
later, the final scan was performed. The endothelium-
independent dilation was expressed as the percentage
change in diameter after GTN administration, relative to
the baseline scan. The same investigator, who was blind to
the subjects’ characteristics, carried out all measurements.
To assess the reproducibility of the measurements, 40 sub-
jects were selected randomly for repeated vascular studies.
The correlation coefficient between the absolute differences
and mean values of paired measurements was 0.92, p < 0.05.b.) Measurement of intima-media thickness; IMT of
the common carotid artery (CCA) was assessed by the
B-mode ultrasound technique. Measurements of IMT
were obtained from the far wall of the distal part of the
CCA (immediately proximal to the carotid bulb) on both
sides. All studies were performed on a single ultrasound
machine (Diasonics VST ultrasound system) using a
linear-array 10-MHz scan head with standardized image
settings, including resolution mode, depth of field, gain,
and transmit focus. All sonograms were obtained with
the patient in the supine position and their head turned
slightly to the contra lateral side. Each ultrasound examin-
ation was performed as an independent study, without
any knowledge of the history of MI and risk factors.
The IMT was measured as the distance from the
leading edge of the near-field (intimal-luminal surface)
and far-field (medial-adventitial) arterial wall. An average
of three measurements on both sides was derived. The
mean IMT was calculated as the average of the left and
right CCA.
c.) Measurement of ankle-brachial pressure index
(ABPI); the systolic blood pressure in both arms was
taken with a blood pressure cuff and Doppler probe,
after a minimum of 10-min rest in the sitting pos-
ition, averaged, and divided into the systolic blood
pressure in the posterior tibial or dorsalis pedis
artery in the leg. The higher reading was used to
determine the ABPI. ABPI was calculated separately
for each leg. The mean ABPI was calculated as the
average of the left and right leg.
Statistical analysis
Variables showing a normal distribution, as determined by
the Kolmogorov-Smirnov test, were expressed as means
and standard deviations. Differences between the two
groups were tested for significance by Student’s t-test for
normally-distributed variables with equal variances, or by
the Welch t-test for variables with unequal variances.
Correlation between normally distributed variables was
tested with the Pearson correlation coefficient. The criterion
for statistical significance was a p value of less than 0.05.
We constructed a multiple linear regression model to
predict VEGF in patients on the basis of classical coronary
risk factors, inflammatory parameters and functional
and structural characteristics of the arterial wall. All
calculations were performed by the IBM SPSS statistics 19
computer program.
A power analysis was performed to calculate the
appropriate sample size to detect significant differ-
ences between the two groups at adequate power. All
calculations, except the power analysis which was
performed with the PASS 11 statistical program, were
performed by the IBM SPSS statistics 19 computer
program.
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Characteristics of the patients and controls at the time of
trial performance
There were no differences in the age of patients and
controls. BMI, but not WHR, was increased in post-MI
patients in comparison to healthy controls. All patients
were taking anti-platelet therapy, 19 (90%) statins
(simvastatin or atorvastatin), 19 (90%) beta-blockers,
and 19 (90%) patients ACE-inhibitors. Subjects in the
control group were not taking any medication.
Because of their medication, patients had signifi-
cantly lower values of LDL cholesterol and lower sys-
tolic blood pressure in comparison to the controls.
The characteristics of the patients and of the controls
at the time of the trial performance are shown in
Table 1.
VEGF, angiogenin and inflammatory molecules in the
patients and controls at the time of trial performance
The patients had significantly higher levels of VEGF
in comparison to the controls (53.8 ± 42.7 pg/ml vs.
36.3 ± 8.9 pg/ml, p = 0.014). The mean values of
VEGF ± one standard deviation in patients and con-
trols are shown in Figure 1. There were no statisti-
cally significant differences in angiogenin levels
between the patients and controls (1.37 ± 0.46 pg/ml
vs. 1.42 ± 0.38 pg/ml, p = 0.318).
The patients had significantly increased IL-6 and
hsCRP in comparison to the controls. The values are
shown in Table 2.Table 1 Characteristics of the subjects and laboratory






Age (years) 42.2 (4.9) 44.8 (5.4) ns
BMI (kg/m2) 25.4 (3.4) 27.3 (2.7) 0.02
Waist-hip ratio (rel.) 0.93 (0.04) 0.94 (0.05) ns
Systolic blood pressure (mmHg) 133 (13) 125 (14) 0.02
Diastolic blood pressure (mmHg) 87 (11) 82 (10) ns
Total cholesterol (mmol/l) 4.99 (0.78) 4.55 (1.0) ns
LDL-cholesterol (mmol/l) 3.11 (0.73) 2.6 (0.87) 0.02
HDL-cholesterol (mmol/l) 1.18 (0.26) 1.02 (0.28) 0.02
TG (mmol/l) 1.50 (0.57) 2.18 (1.57) 0.04
Blood glucose (mmol/l) 5.4 (1.3) 5.9 (1.7) ns
Smokers (N) 4 (16%) 11 (27%) ns
Ex-smokers (N) 4 (16%) 23 (56%) <0.01
Family history (N) 2 (8%) 14 (34%) 0.01
Values are shown as means and standard deviations; p-for the difference
between the two groups, ns-not significant, N-number, BMI-body mass index,
rel.-relative, LDL-low density cholesterol, HDL-high density
cholesterol, TG-triglycerides.Vascular studies
In the patients both FMD and IMT were significantly
increased in comparison to the controls. There were
no significant differences in ABPI between the two groups.
The data are shown in Table 3.
Correlation analysis, multiple linear regression model and
power analysis
In the group of patients, a significant positive correlation
was observed between VEGF and IL-6 (r = 0.37, p = 0.017)
and between VEGF and IL-8 r = 0.45, p = 0.003. The cor-
relations are plotted in Figures 2 and 3. No correlations
between VEGF and parameters of atherosclerotic burden
were obtained.
A multiple linear regression model was constructed to
predict VEGF in the patients on the basis of classical
coronary risk factors, inflammatory parameters and func-
tional and structural characteristics of the arterial wall.
Only factors that were significant in the univariant analysis
were included in the model (IL-6 and IL-8). The adjusted
R2 of this model was 0.226, with a high significance
(p = 0.008). After adjustment only IL-6 (β= 0.338, p = 0.025)
proved to be an independent determinant of VEGF.
We performed post-hoc power and sample size
analysis for comparison between the controls and the
patients regarding the level of VEGF, which was the
main discovery and was found to be significant in
our study. The group sample sizes of 25 and 41 achieve a
74% power to detect a difference of 17.6 between the null
hypothesis that the both group means are 53.9 and the
alternative hypothesis that the mean of group two is 36.3,
with known group standard deviations of 42.7 and 8.9 and
with a significance level (alpha) a = 0.05 using a two-sided
two-sample t-test.
Discussion
The aim of the present study was to explore the role of
VEGF in the stable phase of coronary artery disease. We
found that VEGF was increased in post-MI patients and
furthermore that VEGF values correlated with inflammatory
cytokines (IL-6 and IL-8), but not with parameters
associated with the extent of the atherosclerotic burden.
These results suggest that VEGF in the stable phase after
MI is a part of the inflammatory response and very
likely contributes to worsening of atherosclerosis by
inducing plaque instability. If VEGF were to be involved
in neovascularization as a compensatory mechanism to
ischemia, it would certainly correlate with parameters of
the atherosclerotic burden, but that was not the case.
It has been shown in clinical trials and animal models
that VEGF promotes the development of collateral blood
vessels in response to hypoxia [3,12-14]. All our patients
were in the acute phase of MI, successfully vascularized
(percutaneous trans-luminal angioplasty), and at the time
Figure 1 VEGF in patients and controls. Legend: VEGF- vascular endothelial growth factor, SD-standard deviation.
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symptoms of angina pectoris. It is therefore interesting
that they had increased VEGF levels. Although only a few
studies have explored VEGF in patients with coronary
artery disease, almost all were performed to determine the
role of VEGF in the acute phase of MI where increased
levels of VEGF were found. In one study the peak level for
VEGF was reached during acute MI. After successful
recanalization, the serum levels of VEGF rapidly
(within 20–30 minutes) returned almost completely to
the normal control range [15]. Other studies showedTable 2 Angiogenic and inflammation markers of
subjects at the time of the trial
Parameter Controls (N = 25) Patients (N = 41) p
VEGF (pg/ml) 36.3. ±8.9 53.8 ± 42.7 0.014
Angiogenin (pg/ml) 1.42 ± 0.38 1.37 ± 0.46 0.318
hs CRP (mg/l) 1.5 +/- 1.4 3.5 +/- 8.1 0.038
IL-6 (ng/ml) 2.5 ± 3.4 4.9 ± 4.1 0.016
IL-8 5.4 +/- 1.3 6.3+/- 3.0 0.102
IL-8 (pg/ml) 5.4 ± 1.3 6.3 ± 3.0 0.102
hs CRP (mg/ml) 1.5 ± 1.4 3.5 ± 8.1 0.038
VCAM-1 (ng/ml) 286.5 ± 60.1 283.3 ± 52.1 0.336
ICAM-1 (ng/ml) 182.3 ± 50.3 190.9 ± 44.9 0.775
Selectin-P (ng/ml) 52.9 ± 10.9 55.1 ± 13.4 0.373
Selectin-E (ng/ml) 44.7 ± 12.5 47.4 ± 14.8 0.112
TNF-α (ng/ml) 1.19 ± 1.12 0.93 ± 1.0 0.780
Values are shown as means and standard deviations; VEGF-vascular endothelial
growth factor, IL-6 – interleukin 6, IL-8 – interleukin 8, hsCRP – high sensitive
C-reactive protein, VCAM-1 – vascular cell adhesion molecule-1, ICAM-1 – intra-
cellular adhesion molecule-1, TNF-α – tumour necrosis factor α.that VEGF returns to normal values after about three
weeks or after 6 months [9,10]. The differences in
VEGF normalization time are most probably the result of
different methods of treating AMI (PCI, or conservative
treatment with heparin, which can reduce serum VEGF),
as well as different study populations. There is no data for
a period longer than 6 months.
Thus we explored the values of VEGF in patients
on average 20.5 months after MI and found them to be
increased, which is a new result. However, its explanation
is quite complex. Hence, to clarify this we investigated the
associations of VEGF with both inflammatory molecules
and the atherosclerotic burden, and studied the levels of
angiogenin, another angiogenic factor. The values of
angiogenin were similar in the patients and controls
and did not follow the increase of VEGF, thereby
confirming the pivotal role of VEGF as an angiogenic
factor. Furthermore, to obtain an appropriate answer
to the basic question of the role of VEGF we analysed
a very broad range of both inflammatory molecules
and parameters of the atherosclerotic burden.
Atherosclerosis is a chronic inflammatory disease. In
this context, we were interested whether VEGF is related
to a possible on-going inflammation process. Namely,Table 3 Vascular studies
Parameter Controls (N = 25) Patients (N = 41) p
FMD (%) 8.8 ± 6.5 5.5 ± 4.3 0.017
IMT (mm) 0.68 ± 0.13 0.87 ± 0.17 <0.001
ABPI (rel) 1.17 ± 0.11 1.11 ± 0.13 0.052
FMD-flow mediated dilation, IMT- intima-media thickness, ABPI- ankle brachial
pressure index, p- for the difference between groups.
Figure 2 Correlation between VEGF and IL-6 in patients. Legend: IL-6 - interleukin 6, VEGF- vascular endothelial growth factor, r - correlation
coefficient, p - statistical significance.
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angiogenesis with inflammatory response. In the context
of this study the connection between angiogenesis
and the intravascular arterial wall is of great interest.
Therefore, the intensity of arterial wall inflammation was
measured by the serum levels of different pro-inflammatory
markers (IL-8, IL-6, hsCRP, VCAM1, ICAM1, p-selectin,
e-selectin and TNFα). Importantly, in comparison to theFigure 3 Correlation between VEGF and IL-8 in patients. Legend: IL-8 -
coefficient, p - statistical significance.controls, patients had significantly increased levels of IL-6
and hsCRP, whereas the values of the other inflammatory
molecules were not elevated. Thus, one can conclude that
IL-6 and hsCRP are the best markers of on-going arterial
wall inflammation in the stable phase after MI. On
evaluating the existence of possible associations, we
found significant positive correlations between VEGF
and IL-6, and between VEGF and IL-8. Thus, theseinterleukin 8, VEGF- vascular endothelial growth factor, r - correlation
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levels are related to the intensity of inflammation. This
statement is also confirmed by the model of linear
regression in which IL-6 proved to be an independent
determinant of VEGF. We found no data in the literature
on a correlation between VEGF and IL-6 and IL-8 in
coronary patients. There are only a few studies describing
a correlation between VEGF and different proinflammatory
molecules in patients with coronary artery disease, and
even then only in the acute phase. A positive correlation
between VEGF and hsCRP was found in patients with
acute MI [9,16]. But to the best of our knowledge no
studies describe a correlation between serum VEGF
and IL-6 and IL-8, which has not been examined in
the stable period after MI.
We also explored whether serum VEGF levels were
related to parameters of the atherosclerotic burden,
but did not find any relation. Notably, we did not
find a correlation between VEGF and the severity of
coronary artery disease, classified as one-, two- or
three-vessel coronary artery disease found on the coronar-
ograph. There are only some small and conflicting studies
dealing with VEGF and the extent of coronary artery
disease. Some studies found no correlation between
serum VEGF levels and the severity (extent) of coronary
atherosclerosis in patients measured on the 7th day after
MI, in patients with stable AP and in patients with chest
pain undergoing coronary angiography [17-19]. On the
other hand, in a small Polish study, serum VEGF levels
were higher in AMI patients with multi-vessel disease
than in patients with single-vessel disease [16]. Larger
studies are needed to clarify this relationship. Similarly, we
found no correlation between IMT, measured on the
common carotid artery, and serum VEGF levels.
There are very few data about the association between
IMT and VEGF in patients with coronary artery disease.
In a small study, the authors found no differences in
VEGF levels among patients with stable coronary artery
disease and increased (above 1 mm) or normal IMT
(below 1 mm) [20]. In the present study, we explored
whether plasma VEGF levels were related to endothelial
function, but found no significant correlation between
FMD and VEGF levels. Data on the association of VEGF
with vascular function is again limited. In vitro studies
showed that VEGF is a potent survival factor for endothe-
lial cells [21,22]. It was shown that VEGF gene therapy
may improve endothelial dysfunction in patients with
end-stage coronary artery disease [9].
It is well-known that biomarkers of acute myocardial
ischemia (acute coronary syndrome) are of significant
clinical value and already in clinical use. The following
markers for acute coronary syndrome are FDA-approved:
creatin kinase, myoglobin and cardiac troponin. All three
have become the gold standard for confirmation of acutecoronary syndrome. Several other possible biomarkers are
currently under investigation. However, in contrast, no
clinically useful biomarker for prediction of recurrent
myocardial infarction is currently available. Such a marker
would undoubtedly be very valuable.
Taking all the results together we found that VEGF
values are increased in the stable phase after MI and
correlate with inflammatory markers but not with
parameters of the atherosclerotic burden. Therefore, it
appears logical that VEGF, driven by the inflammatory
process, is involved in the on-going atherosclerosis
process, probably inducing destabilization of coronary
plaques by their neovascularization. On the other hand,
the possibility that increased VEGF levels induce neovas-
cularization in myocardium is much less probable since
VEGF values did not correlate with the parameters of the
atherosclerotic (i.e. ischemic) burden.
The limitations of the present study are that it was
cross-sectional and not prospective and had a relatively
small sample size. However the power of the study was
quite large (74%) and the mentioned limitation did not
affect the main finding of the study, which is increased
VEGF levels in young male patients in the stable phase
after MI.Conclusions
Several biomarkers that predict the clinical prognosis
of patients with acute AMI have been identified. The
relevance of our study is in using VEGF as an additional
cardiovascular biomarker in the chronic stable phase of
coronary artery disease. Conflicting data exists about the
prognostic significance of VEGF levels in the acute
phase after MI, but there is no data about the prognostic
significance of VEGF in the stable phase of coronary
artery disease. According to our findings, VEGF can have
an important negative prognostic value in the stable phase
after MI. This mechanistic study should be followed up by
an observational study to definitively clarify the role of
VEGF as a prognostic marker in patients in the stable
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